Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Biosimilar Statistical Guidance Withdrawn, Expect Sponsor-Specific Advice, FDA's Christl Says

Executive Summary

US FDA's biosimilar chief tells Pink Sheet that sponsors will receive more advice specific to their development programs based on their data package, a practice already in use in some cases.

Advertisement

Related Content

US FDA's Biosimilars Chief Leah Christl Plans Departure
Suffix Smackdown: Gottlieb Calls Issue 'Red Herring' For Biosimilars
Suffix Smackdown: Gottlieb Calls Issue 'Red Herring' For Biosimilars
Industry May Like FDA's Biosimilar Guidance Withdrawal, But Not The New Information Vacuum
US FDA's Biosimilars Program: Five Years In, Complete Response Letters Still Outnumber Approvals
Biosimilars Statistical Guidance Reflects Early Development Approach

Topics

Advertisement
UsernamePublicRestriction

Register

PS123364

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel